Switching to besifovir in patients with chronic hepatitis B receiving tenofovir disoproxil fumarate: A randomized trial.

ABSTRACT:

Background/aims

Besifovir (BSV) showed comparable antiviral activity and superior safety profiles to tenofovir disoproxil fumarate (TDF) in treatment-naïve chronic hepatitis B (CHB). However, no data are available regarding the antiviral efficacy and safety of BSV in patients with CHB who switched from long-term TDF to BSV. This study aimed to evaluate the outcome of a 48-week BSV therapy in patients with CHB who switched from long-term TDF treatment.

Methods

In this non-inferiority trial, 153 CHB patients treated with TDF for ≥48 weeks who had hepatitis B virus (HBV) DNA <20 IU/mL were randomized to receive either BSV 150 mg or TDF 300 mg for 48 weeks.

Results

The per-protocol analysis included 130 patients (BSV group, 64; TDF group, 66). The median duration of TDF u

SUBMITTER: Yim HJ 

PROVIDER: S-EPMC12260639 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature